By Chris Wack


Adamis Pharmaceuticals Corp. said the U.S. Food and Drug Administration has approved its Zimhi naloxone HCL injection 5 mg/0.5 mL product.

Adamis said Zimhi is a high-dose naloxone injection product FDA-approved for use in the treatment of opioid overdose.

Naloxone is an opioid antagonist and is generally considered the drug of choice for immediate administration for opioid overdose. It works by blocking or reversing the effects of the opioid, including extreme drowsiness, slowed breathing, or loss of consciousness, Adamis said.

The company said it is preparing for the full commercial launch of Zimhi in the first quarter of 2022.

Adamis shares were up 21% to $1.35 in premarket trading.


Write to Chris Wack at


(END) Dow Jones Newswires

October 18, 2021 07:55 ET (11:55 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.